SVRA Savara Inc

Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that Rob Neville, Savara’s Chief Executive Officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference in Boston on Tuesday, November 27, 2018 at 11:45 a.m. ET in the South Atlantic Room at the Boston Harbor Hotel in Boston.

Interested parties can access a live audio webcast of the fireside chat on the Investors page of Savara’s website at https://www.savarapharma.com/investors/events/. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation of the webcast will be available on Savara’s website for 30 days.  

About Savara Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2-ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)

Contacts:Savara Inc. IR: Ioana C. Hone (ir@savarapharma.com) (512) 961-1891

Savara Inc. PR and Media:Anne Erickson (anne.erickson@savarapharma.com) (512) 851-1366

For IR: Solebury Trout Gitanjali Jain Ogawa (Gogawa@troutgroup.com) (646) 378-2949